FDA Approves Otarmeni, First Dual-AAV Gene Therapy for Severe Hearing Loss
The FDA has approved Otarmeni, a pioneering gene therapy for severe hearing loss caused by OTOF gene mutations. This landmark approval could transform treatment options and improve quality of life for affected individuals.
· 42d ago
